Consultation
Keely reviews your health history, current medications, BMI, and weight loss goals to determine your starting dose.
Tirzepatide Weight Loss in Indianapolis, IN
Dual-action GLP-1/GIP therapy for clinically significant, sustainable weight loss.
Treatment Type:Weekly injection
Mechanism:Dual GLP-1/GIP agonist
Results Timeline:Measurable loss in 4-8 weeks
FDA Approved:Yes (as Mounjaro / Zepbound)
Why Traditional Diets Fail — and What Science Offers Instead
Understanding Metabolic Resistance
Losing weight can feel impossible when your body actively works against you. Metabolic adaptation, hormonal imbalances, and persistent hunger signals make it incredibly difficult to maintain a calorie deficit through willpower alone. Many patients in Indianapolis have tried countless diets and exercise programs only to regain the weight — or more. The frustration of watching the scale refuse to move despite genuine effort takes a toll on both physical health and emotional well-being.
Tirzepatide addresses weight loss at the hormonal level by activating both GLP-1 and GIP receptors — the first dual-action medication of its kind. This mechanism reduces appetite, slows gastric emptying, and improves insulin sensitivity simultaneously. Keely creates a personalized dosing protocol that gradually increases to your optimal dose, minimizing side effects while maximizing results. Most patients begin seeing measurable weight loss within the first month and can continue their daily routine without interruption.
What Is Tirzepatide?
The Science of Dual-Receptor Agonism
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Originally FDA-approved as Mounjaro for type 2 diabetes and as Zepbound specifically for chronic weight management, compounded tirzepatide is now available through medical providers for weight loss under clinical supervision.
Unlike single-action semaglutide, tirzepatide activates two incretin pathways simultaneously. The GLP-1 component suppresses appetite and slows gastric emptying, while the GIP component enhances insulin sensitivity and may promote greater fat oxidation. In the landmark SURMOUNT-1 trial, participants receiving the highest dose of tirzepatide lost an average of 22.5% of their body weight over 72 weeks — significantly more than any previously available GLP-1 medication.
Treatment Timeline
First Signs
Reduced appetite within 1-2 weeks
Full Effect
Peak weight loss at 60-72 weeks
Treatment Time
Weekly self-injection (under 1 minute)
Recovery
No downtime — continue daily activities
Benefits of Tirzepatide
Superior Weight Loss Through Dual Action
- 01
Dual-Action Mechanism
Only medication targeting both GLP-1 and GIP receptors for enhanced results
- 02
Clinically Proven
Average 22.5% body weight loss demonstrated in SURMOUNT clinical trials
- 03
Weekly Convenience
Simple once-weekly self-injection fits seamlessly into your routine
- 04
Appetite Control
Naturally reduces hunger and food noise without constant willpower
- 05
Metabolic Improvement
Improves insulin sensitivity and cardiovascular health markers beyond weight loss
Tirzepatide vs. Alternatives
Compare Your Options
| Treatment | Mechanism | Time | Results | Duration | Downtime | Best For |
|---|---|---|---|---|---|---|
| Tirzepatide | Dual GLP-1/GIP agonist | Weekly injection | 4-8 weeks onset | Ongoing with use | None | Maximum weight loss, metabolic improvement |
| Semaglutide | GLP-1 agonist only | Weekly injection | 4-8 weeks onset | Ongoing with use | None | Moderate weight loss, established track record |
| Liraglutide | GLP-1 agonist (short) | Daily injection | 2-4 weeks onset | Ongoing with use | None | Patients preferring daily dosing, lower dose range |
| Phentermine | Sympathomimetic amine | Daily oral pill | 1-2 weeks onset | Short-term (12 weeks) | None | Short-term appetite suppression, jump-start |
Who Is a Good Candidate for Tirzepatide?
Finding Your Path to Weight Loss
Compounded tirzepatide is ideal for adults who have struggled to lose weight through diet and exercise alone and are looking for a medically supervised solution. During your consultation, Keely will evaluate your health history, current medications, and weight loss goals to determine if tirzepatide is the right fit.
Ideal Candidates for Tirzepatide
- Adults with a BMI of 30 or higher (obesity) seeking significant weight reduction
- Adults with a BMI of 27 or higher with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia)
- Patients who have not achieved adequate results with diet and exercise programs
- Individuals committed to ongoing medical monitoring and lifestyle modifications
- Those with realistic expectations about gradual, sustained weight loss
Who Should Wait or Avoid Tirzepatide
- Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of severe pancreatitis or active gallbladder disease
- Pregnancy, planning to become pregnant, or currently breastfeeding
- Known hypersensitivity to tirzepatide or any component of the formulation
- History of severe gastrointestinal disease including gastroparesis
Keely conducts a thorough health assessment and reviews your complete medical history before prescribing tirzepatide to ensure your safety throughout treatment.
Tirzepatide Treatment Overview
Initiation
You begin at the lowest dose (2.5 mg weekly) to allow your body to adjust and minimize gastrointestinal side effects.
Titration
Keely increases your dose every 4 weeks based on your tolerance and progress, up to a maximum of 15 mg weekly.
Monitoring
Regular check-ins track your weight, vital signs, and side effects to optimize your dose and ensure safety.
Risks and Side Effects
What to Know
The most common side effects of tirzepatide are gastrointestinal in nature — nausea (reported in up to 31% of patients), diarrhea, decreased appetite, vomiting, and constipation. These effects are typically mild to moderate and most pronounced during the initial weeks of each dose escalation, improving as your body adjusts.
Less common effects may include injection site reactions (redness, itching, or swelling), dizziness, and hair thinning. In rare cases, more serious adverse events have been reported including pancreatitis (less than 1%), gallbladder-related events, and hypoglycemia when combined with insulin or sulfonylureas.
Tirzepatide carries a boxed warning regarding the risk of thyroid C-cell tumors based on rodent studies, though this has not been confirmed in humans. The FDA approved tirzepatide (as Zepbound) for chronic weight management in November 2023.
Keely Phelps PA's careful dose titration protocol and regular monitoring help minimize side effects and ensure a safe, comfortable experience for every patient at Mint Aesthetics & Skin.
Tirzepatide Cost in Indianapolis
Pricing and Payment Options
Tirzepatide in Indianapolis, IN is priced by the vial, with vials ranging from $425 to $550 depending on your dosage. Each vial lasts 4-12 weeks based on your prescribed dose, and vials are shipped directly to your home for convenience. During your consultation, Keely will provide a personalized quote based on your specific treatment plan.
What Affects Your Cost
- Dose level — Higher maintenance doses cost more than lower starting doses
- Vial pricing — Vials range from $425 to $550 and last 4-12 weeks depending on your prescribed dose
- Direct-to-home shipping — Vials are shipped directly to your home, included in your pricing
Mint Aesthetics & Skin accepts financing through Cherry to make your Tirzepatide program more accessible. Many patients find that the health improvements from Tirzepatide therapy reduce other medical costs over time.
Why Choose Mint Aesthetics & Skin
Indianapolis's Trusted Provider
Expert Provider
Clinical expertise in GLP-1 and GIP agonist protocols with personalized dosing
Personalized Care
Customized titration schedules designed for your metabolism and tolerance
Ongoing Monitoring
Regular weight checks and dose adjustments to optimize your trajectory
Comprehensive Approach
Lifestyle guidance and body contouring options for complete transformation
Related Services
View All Services
Related Treatments
Complement your tirzepatide results with these services.
Medical Weight Loss
Advanced Skin Technology
Facials & Skin Treatments
Tirzepatide FAQ
Your Questions Answered
01 What is tirzepatide?
Tirzepatide is a dual GLP-1 and GIP receptor agonist — a once-weekly injectable medication that targets two hormonal pathways to reduce appetite, slow digestion, and improve metabolic function. It is the active ingredient in Mounjaro (for diabetes) and Zepbound (for weight management), and is also available in compounded form through medical providers.
02 How does tirzepatide work for weight loss?
Tirzepatide works by mimicking two natural gut hormones — GLP-1 and GIP. Together, they reduce hunger signals in the brain, slow gastric emptying so you feel full longer, and improve your body's insulin response. This dual mechanism is why tirzepatide has produced greater average weight loss in clinical trials compared to GLP-1-only medications like semaglutide.
03 Tirzepatide vs semaglutide — which is better?
Both are effective GLP-1-based weight loss medications, but tirzepatide's additional GIP receptor activation has shown greater average weight loss in head-to-head data. In clinical trials, tirzepatide patients lost up to 22.5% of body weight compared to approximately 15% with semaglutide. However, individual response varies — Keely can help determine which is best for your situation during a consultation.
04 What are tirzepatide side effects?
The most common side effects are gastrointestinal — nausea, diarrhea, decreased appetite, and constipation. These typically occur during dose increases and improve within 1-2 weeks as your body adjusts. Keely's gradual titration protocol helps minimize these effects. Serious side effects are rare but include pancreatitis and gallbladder events.
05 How much does tirzepatide cost?
Tirzepatide is priced by the vial, with vials ranging from $425 to $550 depending on your dosage. Each vial lasts 4-12 weeks based on your prescribed dose, and vials are shipped directly to your home. Contact Mint Aesthetics & Skin for current pricing and available package options.
06 Is compounded tirzepatide safe?
Compounded tirzepatide is prepared by licensed 503A or 503B compounding pharmacies that follow strict quality and sterility standards. While compounded medications are not FDA-approved products, they contain the same active ingredient. Keely works with reputable pharmacies and monitors your progress closely throughout treatment to ensure safety.
07 What does a tirzepatide dosage chart look like?
Tirzepatide follows a structured titration: you start at 2.5 mg weekly for 4 weeks, then increase to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg — each step lasting at least 4 weeks. Keely adjusts this schedule based on your tolerance and weight loss progress. Not every patient needs to reach the maximum dose.
Location2015 Broad Ripple Avenue
Indianapolis, IN, 46220
Indianapolis, IN, 46220
Phone(317) 748-3169
Schedule Your Tirzepatide Consultation
References
- PubMed (PMID: 35658024) - SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity — participants achieved up to 22.5% body weight reduction vs 2.4% with placebo over 72 weeks (Jastreboff et al., NEJM 2022).
- PubMed (PMID: 36519845) - SURMOUNT-2: Tirzepatide for treatment of obesity in people with type 2 diabetes — mean weight loss of 14.7% at the highest dose over 72 weeks (Garvey et al., Lancet 2023).
- PubMed (PMID: 34170647) - SURPASS-2: Superior glycemic control and weight loss with tirzepatide vs semaglutide 1 mg in type 2 diabetes (Frias et al., NEJM 2021).
- PubMed (PMID: 38389005) - SURMOUNT-3: Tirzepatide maintained 18.4% weight loss at 88 weeks following intensive lifestyle intervention (Wadden et al., Nature Medicine 2024).
- PubMed (PMID: 37385275) - SURMOUNT-4: Continued tirzepatide treatment preserved 18.3% weight loss vs 14.8% regain with placebo withdrawal over 52 weeks (Aronne et al., JAMA 2024).
- FDA - Zepbound (tirzepatide) approved November 2023 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (FDA.gov).